Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Clinical Trials in New York, New York

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma